## RESEARCH AWARDS AND GRANTS:

### PAST

1. **RSG CCE-109777 (Co-investigator) 5%**  
   **American Cancer Society**  
   **Metabolic profiles of residual/recurrent prostate cancer after therapy**  
   **7/1/05 - 6/30/09**  
   **$137,461 direct/year**  
   **$717,198 direct/yr 1-5**

2. **RO1CA101844 (Co-investigator) 5%**  
   **NIH/NCI**  
   **CYP1A1 and CYP1B1 genes in ethnicity-related prostate cancer**  
   **9/1/03-8/31/08**  
   **$178,000 direct/yr 1**  
   **$890,000 direct/yrs 1-5**

3. **Howard Temin Award, K01 CA96618-03 (Co-investigator) 5%**  
   **NIH/NCI**  
   **HR-MAS-Pathologic Correlation of Prostate Tissue Markers**  
   **8/1/02-7/31/07**  
   **$134,500 direct/yr 1**  
   **$672,680 direct/yrs 1-5**

4. **VA Merit Review, MREP (Co-investigator) 5%**  
   **VA Merit Review**  
   **CYP1B1 polymorphisms in ethnicity-related prostate cancer**  
   **7/1/04-6/30/07**  
   **$129,000 direct/yr1**  
   **$387,000 direct/yrs 1-5**

5. **R01 CA102751 (Co-investigator) 5%**  
   **NIH/NCI**  
   **MR Based Molecular Imaging of Prostate Cancer**  
   **1/1/05-12/31/09**  
   **$361,240 direct/yr 1**  
   **$1,806,197 direct/yrs 1-5**

6. **DAMD17-03-2-0055 (Co-Investigator) 5%**  
   **AdMeTech Foundation**  
   **Molecular Imaging of Prostate Cancer**  
   **09/21/09 – 07/31/11**  
   **$49,000/yr**  
   **$99,000 Total**

7. **W81XWH-10-1-0334 (Co-Investigator) 3%**  
   **DOD**  
   **Discovery of Hyperpolarized Molecular Imaging Biomarkers**  
   **05/15/2010-05/14/2013**  
   **$133,000/yr**  
   **$388,375 Total**

8. **RO1CA130860-01 (Co-Investigator) 5%**  
   **NIH/NCI**  
   **Wnt antagonist genes in kidney tumor progression and metastasis**  
   **08/1/2008-07/30/2013**  
   **$387,000 direct/yr1**  
   **$1,935,000 Total**

### CURRENT

1. **RO1CA138642-01 (Co-Investigator) 5%**  
   **NIH/NCI**  
   **MicroRNAs in the progression and metastasis of prostate cancer**  
   **04/01/2010-3/31/2015**  
   **$356,000/yr**  
   **$1,780,000 Total**

2. **Veterans Affairs Merit Review Award (Co-Investigator) 3%**  
   **Department of Veterans Affairs**  
   **Polymorphisms of estrogen-metabolizing genes in kidney cancer**  
   **$300,000/yr**  
   **$1,200,000 Total**

3. **Veterans Affairs Program Project Award (Co-Investigator) 5%**  
   **1/2012-12/2015**
Laura Tabatabai, MD

Department of Veterans Affairs
$263,000/yr
Polymorphisms of DNA mismatch repair as risk factors for prostate ca $790,000 Total

PEER REVIEWED PUBLICATIONS:


5. ZL Tabatabai, GA Staerkel. Distinguishing primary and metastatic conventional renal cell carcinoma from other malignant neoplasms in fine needle aspiration biopsy specimens. *Arch Pathol Lab Med*. 129(8):1017-21, 2005


**ABSTRACTS:**


3. L. Tabatabai, D. Lewis, F. Gordon, R. Jenkins, U. Khettry, Recurrence-free Survival after Liver Transplantation (LT) for Chronic Hepatitis B (HB), *Mod Pathol*, 12 (1999);428A


magnetic angle spinning (HR-MAS) spectroscopy. 1st Annual Imaging Research Symposium, UCSF Dept. of Radiology, May 4, 2004


20. ZL Tabatabai, LD Ferrell. Reticulin, Copper, and CD34 Staining in the Diagnosis of Focal Nodular Hyperplasia. *Mod Pathol* 18 (2005);287A


24. Takashi Tokizane, Hiroaki Shiina, Hideki Enokida, Shinji Urakami, Toshifumi Kawakami, Tatsuya Ogishima, Steven Okino, Long-Cheng Li, Kirsten L Greene, Laura Tabatabai, Christopher J Kane, Peter R Carroll, Norio Nonomura, Nobuhisa Ishii, Mikio Igawa, Akihiko Okuyama, Rajvir Dahiya. Cytochrome P450 1B1 is over-expressed and regulated by hypomethylation in human prostate cancer. *J Urol* 173 (2005);63


26. Hiroaki Shiina, Hideki Enokida, Shinji Urakami, Tatsuya Ogishima, Toshifumi Kawakami, Long-Cheng Li, Hirofumi Kishi, Kazushi Shigeno, Leopoldo A Ribeiro-Filho, Alvaro S Sarkis, Laura Tabatabai, Christopher J Kane, Peter R Carroll, Mikio Igawa, Rajvir Dahiya. Single nucleotide polymorphism (SNP) and splicing variant in C-terminal region of TCF-4 gene are related to the pathogenesis of prostate cancer. *J Urol* 173 (2005);106

27. Hideki Enokida, Hiroaki Shiina, Mikio Igawa, Tatsuya Ogishima, Toshifumi Kawakami, Shinji Urakami, Long-Cheng Li, Kirsten L. Greene, Motoshi Kawahara, Masayuki Nakagawa, Z. Laura Tabatabai, Christopher J. Kane, Peter R. Carroll, Rajvir Dahiya. CpG hypermethylation of *MDR1* gene contributes to the pathogenesis and progression of human prostate cancer. *J Urol* 173 (2005);123


29. Shinji Urakami, Hiroaki Shiina, Hideki Enokida, Toshifumi Kawakami, Takashi Tokizane, Tatsuya Ogishima, Kirsten L Greene, Hiroyuki Adachi, Z Laura Tabatabai, Christopher J Kane, Peter R Carroll, Akihiko Okuyama, Mikio Igawa, Rajvir Dahiya. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder carcinogenesis through aberrant Wnt signaling activation. *J Urol* 173 (2005);209


34. Lorren Jackson, Z. Laura Tabatabai. Utility of Fine Needle Aspiration Cytology (FNAC) in the Evaluation of Superficial, Palpable Masses Clinically Presumed to be Lymph Nodes: A 5-year Retrospective Review with Histopathological and Clinical Correlation. Mod Pathol 19 (2006);34A

35. Raga Ramachandran, Judy Pang, Z. Laura Tabatabai. Pancreatic Intraductal Papillary Mucinous Tumor (IPMT): A Cytomorphologic Study with Histopathological Correlation. Mod Pathol (2007);81A


46. Koji Ueno, Hiroshi Hirata, Z. Laura Tabatabai, Yuji Hinoda, Peter Carroll, Rajvir Dahiya. IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces M-CAM expression in human renal cell carcinoma. *J Urol* 185 (2011);e46


53. SM Calkins, ZL Tabatabai. Value of Napsin-A and TTF-1 Immunostains in the Distinction of Mesothelioma from Metastatic Pulmonary and Non-Pulmonary Adenocarcinoma from Mesothelioma and Metastatic Non-Pulmonary Adenocarcinoma in Effusion Samples. *Arch Pathol Lab Med* (2012)


58. SM Barcia, SM Nobles, ZL Tabatabai. Evaluation of Small Kidney Masses in the Era of Tumor Ablation Therapy—How Accurate is Rapid Cytological Diagnosis and Should Separation of the Diagnostic and Treatment Procedures be Considered? Mod Pathol, 26 (2013); 84A


OTHER PUBLICATIONS/CREATIVE ACTIVITIES:


